Info

🌱 來自：Systemic therapy for metastatic clear cell RCC

First-line therapies-of-renal-cell-carcinoma

Favorable

• Cabozantinib+nivolumab
• Lenvatinib+pembrolizumab
• Axitinib+pembrolizumab

Other

• Sunitinib
• Pazopanib
• Ipilimumab+nivolumab
• Axitinib+avelumab
• Cabozantinib
• High-dose IL-2a
• Axitiniba
• Surveillancea

---

Intermediate/Poor

• Cabozantinib+nivolumab
• Lenvatinib+pembrolizumab
• Axitinib+pembrolizumab
• Ipilimumab+nivolumab
• Cabozantinib

Other

• Axitinib+avelumab
• Sunitinib
• Pazopanib
• Axitiniba
• High-dose IL-2a
• Temsirolimusa